Home Biosimilar Antibodies Immunology & Inflammation CD markers Cusatuzumab (Anti-TNFSF7 / CD27L / CD70)
For research use only. Not for use in humans.

Cusatuzumab (Anti-TNFSF7 / CD27L / CD70)

Synonyms: null

Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD.

Cusatuzumab (Anti-TNFSF7 / CD27L / CD70)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A274701 Purity: 99% Protein concentration: 10.72mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD.
References

Product Details

CAS No. 1399546-01-0
Molecular Weight 144.36
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07164469 NOT_YET_RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide|Drug: CD70.CAR NK C Large B-cell Lymphoma; Hodgkin Lymphoma M.D. Anderson Cancer Center 2026-12-28 PHASE2
NCT06946680 NOT_YET_RECRUITING High-grade Glioma; Diffuse Intrinsic Pontine Glioma University of Florida 2026-07 PHASE1
NCT06326463 RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide|Drug: CD70-CAR T ce Hematologic Malignancy; ALL, Childhood; AML, Childhood; Lymphoma; MDS St. Jude Children's Research Hospital 2024-10-16 PHASE1
NCT07676006 NOT_YET_RECRUITING Relapsed/Refractory Acute Myeloid Leukemia (AML) Grit Biotechnology 2026-07-01 EARLY_PHASE1
NCT05438368 NOT_YET_RECRUITING Cancer Disease Shenzhen Geno-Immune Medical Institute 2026-12-31 PHASE1; PHASE2
NCT07569263 NOT_YET_RECRUITING Brain Metastases University of Florida 2026-07 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-15)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.